End-of-dose akinesia after a single intravenous infusion of the Dopaminergic Agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Movement Disorders

Volumn 20, Issue 7, 2005, Pages 803-809

  Simon, Nicolas ^a   Micallef, Joëlle ^a   Reynier, Jean Charles ^a   Lesourd, Monique ^b   Witjas, Tatiana ^a   Alicherif, André ^a   Azulay, Jean Philippe ^a   Blin, Olivier ^a  

^a TIMONE HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Akinesia; Intravenous; Parkinson's disease; Pharmacokinetics pharmacodynamics; Piribedil; Randomized double blind study

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PIRIBEDIL; PLACEBO; ROPINIROLE; TRIHEXYPHENIDYL;

ABDOMINAL PAIN; ADULT; AGED; AKINESIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; IDIOPATHIC DISEASE; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA AND VOMITING; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYMPTOMATOLOGY;

AGED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRIBEDIL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 24144449547     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20400     Document Type: Article

References (21)

1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential profile of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
2. 2-adrenoreceptor. J Pharmacol Exp Ther 2002;303:805-814.
3. 2-adrenoreceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001;297:876-887.
4. Jenner P. Parkinson's disease: pathological mechanisms and acceptance of piribedil. J Neurol 1992;239(Suppl.):2-8.
5. Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-treated common marmosets. Mov Disord 1996; 11:125-135.
6. Rondot P, Ziegler M. Activity and acceptability of Trivastal in Parkinson's disease: a multicenter study. J Neurol 1992; 239(Suppl.):28-34.
7. Kwiecinski H, Fedorova N, Takats A, Ruzicka E, Jamrozik Z, Del Signore S. A multicenter trial of piribedil as early adjunct treatment for Parkinson's disease: piribedil international study group. Neurology 2002;58(Suppl.):163.
8. Ziegler M, Castro-Caldas A, Del Signore S, et al. Efficacy of piribedil in akinetic-hypertonic Parkinsonian patients after 4-month combination treatment with L-dopa. Parkinsonism Relat Disord 2001;7(Suppl.):1-133.
9. Chezaubernard C, Klippert P, Jeanniot JP, Grislain L, Papalexiou A. Piribedil: nouvelles donnees de pharmacocinetique et de metabolisme chez l'homme. JAMA 1991;(French edition: special issue):21-25.
10. Ziegler M, Spampinato U, Rondot P, et al. Cinetique plasmatique du piribedil par voie intraveineuse et correlation avec le tremblement parkinsonien. JAMA 1991;(French edition: special issue): 26-30.
11. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D; the Parkinson Study Group. The placebo response in Parkinson's disease. Clin Neuropharmacol 1999;22:207-212.
12. Rascol O, Blin O, Thalamas C, et al. ABT-431, a D1 receptor agonist pro-drug has efficacy in Parkinson's disease. Ann Neurol 1999;45:736-741.
13. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease, Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153-163, 293-304.
14. Ziegler M, Del Signore S, Bonhomme C, Spampinato U. Resting tremor is inversely related to piribedil plasma concentration after intravenous administration in parkinsonian patients. Parkinsonism Relat Disord 2001;7(Suppl):257.
15. Hubble J. Long-term studies of dopamine agonists. Neurology 2002;58(Suppl.):42-50.
16. Van Laar T, Van der Geest R, Danhof M, Bodde HE, Goossens PH, Roos RA. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin Neuropharmacol 1998;21:152-158.
17. Calabrese VP, Lloyd KA, Brancazio P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov Disord 1998;13:768-774.
18. Ruggieri S, Stocchi F, Carta A, et al. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Mov Disord 1988;3:313-319.
19. De la Fuente-Fernandez R, Ruth TJ, Sossi V, Schultzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-1166.
20. De la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-306.
21. Simon N, Frey N, Micallef J, Reymer JC, Lesourd M, Witjas T. A pharmacokinetic/pharmacodynamic study on akinesia following a single intravenous infusion of piribedil in Parkinson's disease patients [abstract P244]. Mov Disord 2002;17(Suppl. 5):S86.